Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 19 04:00PM ET
14.11
Dollar change
-0.25
Percentage change
-1.74
%
CategoryUS Equities - Industry Sector Asset TypeEquities (Stocks) TagsU.S. Return% 1Y13.97% Shs Outstand Perf Week-9.78%
SponsorExchange Traded Concepts ETF Type Tagsequity Return% 3Y-19.25% Total Holdings79 Perf Month-12.90%
Fund Family Bond Type Tagsbiotechnology Return% 5Y-5.65% AUM17.74M Perf Quarter5.93%
IndexLoncar Cancer Immunotherapy Index Average Maturity Tagspharmaceutical Return% 10Y NAV% Perf Half Y40.12%
Index Weighting Commodity Type Tagscancer Return% SI NAV/sh Perf Year11.98%
Active/Passive Quant Type Tags- Flows% 1M-16.94% 52W Range9.22 - 17.96 Perf YTD4.75%
Dividend TTM- ESG Type Tags- Flows% 3M26.72% 52W High-21.44% Beta0.92
Dividend Ex-DateDec 29, 2021 Dividend Type Sector/Theme Flows% YTD26.72% 52W Low53.04% ATR (14)0.47
Expense0.79% Structure Type Region Flows% 1Y RSI (14)32.46 Volatility2.87% 2.68%
Option/ShortNo / Yes Growth/Value Dev/Emerg Flows% 3Y Rel Volume0.40 Prev Close14.36
Inverse/Leveraged Market Cap Currency Flows% 5Y Avg Volume37.76K Price14.11
SMA20-10.05% SMA50-12.51% SMA2008.52% Trades Volume14,963 Change-1.74%
Oct-23-23 08:30AM
Mar-15-21 06:06PM
Sep-18-20 05:46AM
May-18-20 10:51AM
Mar-26-20 12:00AM
07:17PM Loading…
Jan-26-20 07:17PM
Jan-23-20 04:15PM
Dec-24-19 12:15PM
Dec-23-19 12:00PM
Dec-10-19 10:10AM
Dec-02-19 02:40PM
Nov-29-19 12:15PM
Nov-21-19 12:15PM
Nov-14-19 01:31PM
Nov-01-19 03:18PM
03:11PM Loading…
Jun-05-19 03:11PM
Jun-03-19 02:46PM
May-09-19 07:46AM
Mar-20-19 07:00AM
Mar-12-19 11:05AM
Mar-11-19 10:59AM
Mar-06-19 05:05PM
Feb-06-19 02:32PM
Aug-16-18 11:49AM
Aug-15-18 08:00AM
Aug-02-18 12:55PM
10:47AM
Jun-28-18 06:56AM
Apr-18-18 04:08PM
Apr-11-18 09:26PM
01:30PM Loading…
Mar-16-18 01:30PM
Feb-28-18 02:09PM
Feb-20-18 09:24AM
Feb-16-18 08:00AM
Feb-02-18 08:00AM
Dec-20-17 08:00AM
Dec-18-17 02:40PM
Nov-14-17 04:18PM
Oct-04-17 08:00AM
Sep-01-17 02:06PM
Aug-28-17 02:37PM
Jun-22-17 04:02PM
Jun-21-17 08:30AM
Jun-02-17 06:56AM
Nov-16-16 05:22PM
Oct-28-16 03:31PM
Oct-25-16 12:47PM
Oct-14-16 08:30AM
Aug-06-16 12:07PM
Aug-02-16 12:09PM
Jun-22-16 07:30AM
Jun-01-16 09:23AM
Apr-12-16 04:22PM
Mar-07-16 06:37AM
Feb-16-16 05:12AM
Feb-10-16 09:29AM
Feb-08-16 06:33PM
Feb-05-16 06:46AM
Jan-08-16 01:33PM
Dec-16-15 07:00AM
Dec-14-15 05:46PM
Dec-05-15 12:01AM
12:01AM
Dec-01-15 09:50AM
Nov-30-15 11:31AM
Oct-16-15 03:23PM
12:12PM
Oct-15-15 05:15PM
Oct-14-15 09:05AM
Loncar Cancer Immunotherapy ETF seeks to track the total return performance, before fees and expenses, of the Loncar Cancer Immunotherapy Index. The index is composed of the common stock of approximately 30 pharmaceutical or biotechnology companies identified by the fund's index provider, as having a high strategic focus on the development of drugs that harness the body's own immune system to fight cancer. The adviser attempts to invest all, or substantially all, of its assets in the component securities and ADRs that make up the index. At least 80% of its total assets will be invested in the component securities of the index. The fund is non-diversified.